Slingshot Insights | Rdus Overview

RDUS Overview

Upcoming Projects (RDUS)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (RDUS)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (RDUS)

Evaluating the Chances of Approval and Market Potential for Radius Health's (RDUS) Abaloparatide-SC for Postmenopausal Women with Osteoporosis
Tickers: RDUS, AMGN, LLY
Execute By: May 09, 2017

Upcoming & Overdue Catalysts (RDUS)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (RDUS)

RDUS Phase 2b Data for Elacestrant (RAD1901) for Postmenopausal Vasomotor Symptoms Expected Second Half 2017 - Discontinued
Ticker: RDUS
Occurred on: Dec 07, 2017
PDUFA Date of June 30th for Radius' (RDUS) NDA for Abaloparatide-SC in Treatment of Postmenopausal Women with Osteoporosis
Ticker: RDUS
Occurred on: Apr 28, 2017
Radius Health (RDUS) to Complete Phase III Testing in October 2016 for Abaloparatide-SC in Postmenopausal Osteoporosis
Ticker: RDUS
Occurred on: Aug 16, 2016
NDA filing of Abaloparatide-SC for Osteoporosis due by the end of 1Q 2016
Ticker: RDUS
Occurred on: May 31, 2016
Radius Health (RDUS) Presented Pre-specified Subgroup Analyses from Phase 3 ACTIVE Trial Evaluating Abaloparatide-SC in Postmenopausal Women With Osteoporosis at ENDO 2016 Annual Meeting
Ticker: RDUS
Occurred on: Apr 01, 2016
EMA Validates Marketing Authorization Application for Abaloparatide-SC for the Treatment of Osteoporosis in Postmenopausal Women, NDA submission to FDA expected by the end of the first quarter of 2016
Ticker: RDUS
Occurred on: Mar 30, 2016
Radius Health (RDUS) Submits New Drug Application (NDA) to FDA for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
Ticker: RDUS
Occurred on: Mar 30, 2016

Strategic Initiatives (RDUS)

Don’t see a strategic initiative related to the company you care about? Create your own!